President Donald Trump issued an executive order on Wednesday, April 1, 2026, from the Cross Hall of the White House in Washington, D.C., outlining a new tariff structure designed to encourage pharmaceutical companies to bring manufacturing back to the United States and secure favorable pricing agreements.

Incentivizing Domestic Production

The core of the order centers on reducing tariffs for companies that commit to establishing manufacturing facilities within the U.S. Tariffs will be reduced to 20 percent for companies that choose to reshore their production. An even greater benefit is offered to companies willing to negotiate pricing with the government.

Most Favored Nation Agreements

Companies that commit to U.S.-based manufacturing and enter into a most-favored-nation agreement with the Department of Health and Human Services (HHS) could potentially avoid tariffs altogether while building their new plant. This dual approach demonstrates the administration’s desire to increase domestic production and control pharmaceutical pricing.

Implementation and Transition

Large companies, as defined by the order, will have a 120-day phase-in period to adjust to the new tariff rates. This grace period is intended to minimize disruptions to the supply chain and allow for a smoother transition.

Existing Trade Agreements

The executive order includes exemptions for pharmaceutical products originating from countries with existing trade agreements with the U.S. Drugs manufactured in Switzerland, Japan, South Korea, and the 27-member European Union will be subject to a 15 percent tariff, rather than potentially higher rates.

Balancing Trade Relationships

This distinction acknowledges established trading partnerships and reflects a pragmatic approach to trade policy. The administration recognizes the need to balance broader economic goals with pre-existing agreements.

Overarching Goals and Policy Shift

The overarching goal is to restructure the pharmaceutical supply chain and incentivize domestic production. The administration hopes to create a “win-win” scenario where American consumers benefit from lower drug prices and companies potentially increase profits through expanded U.S. sales.

This policy represents a more interventionist approach to trade, prioritizing domestic manufacturing and reshaping international trade agreements to serve national interests. It signifies a significant shift in the administration's approach to the pharmaceutical industry and trade policy.